Phase 3 N=468 Brexpiprazole in Patients With Acute Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 6 in PANSS Total Score — -15.9; -20.0; -24.0 units on a scale — p=0.0560
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=259 An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — 98.1; 97.7; 97.4; 97.2 units on a scale — p=0.2053
N/A N=14 First Episode Schizophrenia and Cannabis-Related Disorder Study
Cannabis-Related Disorder · Substance-Related Disorders · Schizophrenia
Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants
N/A N=404 An Integrated Program for the Treatment of First Episode of Psychosis
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Mean Heinrichs-Carpenter Quality of Life Scale Scores Over Time — 51.25; 55.13; 59.15; 60.08 score on a scale — p=0.0145
Phase 3 N=401 A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -23.9; -22.8; -17.5 units on a scale — p=<0.001
Phase 3 N=187 Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)
Schizophrenia
Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants
Phase 2 N=359 Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 4 in the PANSS Total Score — -14.28; -13.95; -16.08; -9.27 score on a scale — p=0.0009
Phase 2 N=245 A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -9.7; -17.2 Units on a scale — p=0.001
Phase 2 N=224 An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)
Schizophrenia, Acute Episode
Primary: Least Squares Mean (LSM) Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -14.6; -17.2; -10.0 Score on a Scale — p=0.440
Phase 3 N=386 To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
Schizophrenia
Primary: Time to Relapse or an Impending Relapse — 0; 3; 1; 14 relapses
Phase 4 N=198 Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
Schizophrenia
Primary: Percentage of Participants That Responded to Treatment — 62.8; 56.8 percentage of response — p=.61
Phase 3 N=674 Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia
Acute Schizophrenia
Primary: Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score. — -3.32; -4.35; -5.58; -3.48 Units on a scale — p=0.0093
Phase 3 N=49 Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
Schizophrenia
Primary: Mean Change From Baseline to Week 16 in Positive and Negative Syndrome Scale (PANSS) Total Score — -10.2 Units on a scale — p=<0.0001
Phase 3 N=340 Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Schizophrenia
Primary: Mean Change From Baseline to Endpoint in Positive and Negative Syndrome Scale (PANSS) Total Score. — -8.9; -5.0; -15.2; -8.3 Units on a scale — p=0.0005
Phase 4 N=491 PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia
Schizophrenia
Primary: Percentage of Participants Assessed as Very Much Improved or Much Improved Based on Clinical Global Impression-Improvement (CGI-I) Scale - Intent-to-treat (ITT)…
Phase 2 N=164 A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Symptom Scale (PANSS) Total Score at Week 6 — -14.08; -19.54 score on a scale — p=0.115
Phase 2 N=216 A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)
Schizophrenia
Primary: Mean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) at Week 4 — -13.3; -17.0; -12.7 Units on a scale — p=0.8590
Phase 3 N=360 A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)
Schizophrenia
Primary: Change From Baseline in PANSS Total Score at Day 42 — -17.4; -21.7; -21.6; -16.2 score on a scale — p=0.6043
Phase 4 N=60 Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
Schizophrenia
Primary: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 6.7; 0.9; 3.9; 5.9 T scores — p=<0.03
Phase 3 N=508 Safety and Efficacy of MP-214 in Patients With Schizophrenia
Schizophrenia
Primary: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 — -10.4; -13.8; -14.0; -20.2 units on a scale
Phase 3 N=97 Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score — -22.9; -19.4 Units on a scale — p=<0.0001
Phase 2 N=459 Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score (Double Blind Phase) — -9.76; -18.73; -16.19; -18.25 Units on a scale — p=0.2846
Phase 3 N=186 Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
Schizophrenia
Primary: Overall Relapse Rate (in Percent) From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse. — 19.39; 37.50 relapse rate(percentage of participants)…
Phase 2 N=499 Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 — -20.7; -18.5; -24.0; -17.8 Score on a scale — p=0.241
Phase 3 N=117 Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials
Schizophrenia
Primary: Mean Clinical Global Impression Severity Score (CGI-S) From Baseline Through End of Study- - Safety Population. — 2.6; 1.0; 2.3; 1.1 units on a scale
N/A N=165 Biomarkers in First Episode Schizophrenia
Schizophrenia · Schizophreniform Disorder · Schizoaffective Disorder, Depressed Type
Primary: Biomarkers — 287.37; 340.83; 492.33; 420.17 pg/mL
N/A N=20 Clinical Trial of Dipyridamole in Schizophrenia
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change in Positive Symptoms by Treatment Assignment — 2.222; 1.400; 1.60; 1.00 units on a scale
Phase 4 N=628 Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Changes From Study Period II Baseline (Week 0) to Weeks 3, 4, 6, 8, and 12 in Positive and Negative Syndrome Scale (PANSS) Total Score in Early Onset Response and Not…
Phase 3 N=23 Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
Alcohol Dependence · Schizophrenia
Primary: Number of Drinking Days — 10.7; 7.6 days
Phase 3 N=623 A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
Schizophrenia
Primary: The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score — -20.9; -21.8; -9.8 units on a scale — p=<0.001